Daisuke Ennishi

6.4k total citations
109 papers, 1.5k citations indexed

About

Daisuke Ennishi is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Daisuke Ennishi has authored 109 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pathology and Forensic Medicine, 43 papers in Oncology and 25 papers in Genetics. Recurrent topics in Daisuke Ennishi's work include Lymphoma Diagnosis and Treatment (50 papers), Chronic Lymphocytic Leukemia Research (19 papers) and CAR-T cell therapy research (18 papers). Daisuke Ennishi is often cited by papers focused on Lymphoma Diagnosis and Treatment (50 papers), Chronic Lymphocytic Leukemia Research (19 papers) and CAR-T cell therapy research (18 papers). Daisuke Ennishi collaborates with scholars based in Japan, Canada and United States. Daisuke Ennishi's co-authors include David W. Scott, Mitsune Tanimoto, Randy D. Gascoyne, Christian Steidl, Joseph M. Connors, Yoshinobu Maeda, Kiyohiko Hatake, Kengo Takeuchi, Yuko Mishima and Anja Mottok and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Daisuke Ennishi

90 papers receiving 1.5k citations

Peers

Countries citing papers authored by Daisuke Ennishi

Since Specialization

Citations

This map shows the geographic impact of Daisuke Ennishi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daisuke Ennishi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daisuke Ennishi more than expected).

Fields of papers citing papers by Daisuke Ennishi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daisuke Ennishi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daisuke Ennishi. The network helps show where Daisuke Ennishi may publish in the future.

Co-authorship network of co-authors of Daisuke Ennishi

This figure shows the co-authorship network connecting the top 25 collaborators of Daisuke Ennishi. A scholar is included among the top collaborators of Daisuke Ennishi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daisuke Ennishi. Daisuke Ennishi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real‐World Data of Comprehensive Cancer Genomic Profiling Tests Performed in the Routine Clinical Setting in Sarcoma 2025 ·Cancer Medicine ·Eiji Nakata, Daisuke Ennishi, (unknown), Kiichiro Ninomiya, Shuta Tomida, (unknown), Tomohiro Fujiwara, Toshiyuki Kunisada, (unknown), Hideki Yamamoto, (unknown), (unknown), Hiroyuki Yanai, Akira Hirasawa, Shinichi Toyooka, Masahiro Tabata, Toshifumi Ozaki	1
2	Distinct age-related effects of homologous recombination deficiency on genomic profiling and treatment efficacy in gastric cancer 2025 ·Journal of Gastroenterology ·(unknown), Yoshiyasu Kono, (unknown), Hideki Yamamoto, (unknown), Daisuke Ennishi, Shuta Tomida, Shinichi Toyooka, (unknown), Masaya Iwamuro, Seiji Kawano, Motoyuki Otsuka	0
3	Recurrent Cerebral Hemorrhaging with Platelet Dysfunction Accompanied by Anti-glycoprotein VI Autoantibodies in a Patient with TAFRO Syndrome 2024 ·Internal Medicine ·Akira Yamamoto, Hisakazu Nishimori, Toshiaki Shirai, Katsuhiro Takano, (unknown), (unknown), (unknown), (unknown), Noboru Asada, Daisuke Ennishi, Keiko Fujii, Nobuharu Fujii, (unknown), Kenji Niiya, Katsue Suzuki‐Inoue, Yoshinobu Maeda	0
4	Evolving molecular classification of aggressive B‐cell lymphoma 2024 ·Histopathology ·Stefan Alig, Bjoern Chapuy, Daisuke Ennishi, Kieron Dunleavy, Daniel J. Hodson	0
5	Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report 2024 ·JCO Precision Oncology ·Kiichiro Ninomiya, Daisuke Ennishi, Kunio Okamoto, Midori Ando, Satoko Nakamura, Shuta Tomida, (unknown), Go Makimoto, Eiki Ichihara, Natsuko Okita, Shinichi Toyooka, Yoshinobu Maeda, Masahiro Tabata	0
6	Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma 2024 ·SHILAP Revista de lepidopterología ·Hiroki Kobayashi, Ryota Chijimatsu, (unknown), Yoshihiro Otani, (unknown), (unknown), Joji Ishida, Hiroyuki Murakami, Hideki Ujiie, (unknown), (unknown), (unknown), Hideaki Fujiwara, Noboru Asada, Nobuharu Fujii, Ken‐ichi Matsuoka, Yasuharu Sato, (unknown), Daisuke Ennishi	2
7	Outcomes of allogeneic SCT versus tisagenlecleucel in patients with R/R LBCL and poor prognostic factors 2024 ·International Journal of Hematology ·(unknown), Toshiki Terao, Hisakazu Nishimori, (unknown), Hiroki Kobayashi, (unknown), (unknown), Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Keiko Fujii, Nobuharu Fujii, Ken‐ichi Matsuoka, Yoshinobu Maeda	2
8	Understanding the intrinsic biology of diffuse large B-cell lymphoma: recent advances and future prospects 2024 ·International Journal of Hematology ·(unknown), Daisuke Ennishi	3
9	Negative Prognostic Impact of High-Dose or Long-Term Corticosteroid Use in Patients with Relapsed or Refractory B-Cell Lymphoma Who Received Tisagenlecleucel 2023 ·Transplantation and Cellular Therapy ·Toshiki Terao, (unknown), Nobuharu Fujii, Noboru Asada, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Hideaki Fujiwara, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Ken‐ichi Matsuoka, Yoshinobu Maeda	4
10	Hematopoietic stem cell–derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide 2023 ·JCI Insight ·(unknown), (unknown), Shuntaro Ikegawa, (unknown), (unknown), Midori Filiz Nishimura, (unknown), (unknown), Makoto Nakamura, Yusuke Meguri, Takashi Matsushita, Naoki Tanimine, Maiko Kimura, Noboru Asada, Daisuke Ennishi, Yoshinobu Maeda, Ken‐ichi Matsuoka	4
11	Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study 2022 ·International Journal of Hematology ·Hideki Goto, Koji Izutsu, Daisuke Ennishi, Yuko Mishima, Shinichi Makita, Koji Kato, (unknown), Satoshi Hirano, (unknown), Takanori Teshima, Hirokazu Nagai, Kenichi Ishizawa	9
12	Chronic active Epstein–Barr virus infection presenting as refractory chronic sinusitis 2022 ·International Journal of Hematology ·(unknown), Hideaki Fujiwara, (unknown), Takaya Higaki, Rei Shibata, (unknown), (unknown), Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken‐ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda	1
13	Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study 2021 ·Cancer Science ·Koji Izutsu, Kiyoshi Ando, Daisuke Ennishi, Hirohiko Shibayama, Junji Suzumiya, Kazuhito Yamamoto, Satoshi Ichikawa, Koji Kato, Kyoya Kumagai, Priti Patel, (unknown), Nobuya Hayashi, (unknown), (unknown), Hirokazu Nagai	8
14	Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification 2021 ·Blood ·Michael Nissen, Xuehai Wang, Clémentine Sarkozy, Aixiang Jiang, Daisuke Ennishi, Tomohiro Aoki, Stacy Hung, Elizabeth A. Chavez, Jeffrey W. Craig, Pedro Farinha, Graham W. Slack, David W. Scott, Christian Steidl, Andrew P. Weng	0
15	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology 2018 ·Blood ·David W. Scott, Rebecca L. King, Annette M. Staiger, Susana Ben‐Neriah, Aixiang Jiang, Heike Horn, Anja Mottok, Pedro Farinha, Graham W. Slack, Daisuke Ennishi, Norbert Schmitz, Michael Pfreundschuh, Grzegorz S. Nowakowski, Brad S. Kahl, Joseph M. Connors, Randy D. Gascoyne, German Ott, William R. Macon, Andreas Rosenwald	145
16	Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management 2018 ·Journal of Molecular Diagnostics ·Stacy Hung, Barbara Meissner, Elizabeth A. Chavez, Susana Ben‐Neriah, Daisuke Ennishi, Martin Jones, Hennady P. Shulha, Fong Chun Chan, Merrill Boyle, Robert Kridel, Randy D. Gascoyne, Andrew J. Mungall, Marco A. Marra, David W. Scott, Joseph M. Connors, Christian Steidl	53
17	Deciphering Discordance between MYC mRNA and MYC IHC in DLBCL: The Role of MYC Exon 2 Mutations and N11S Polymorphism 2017 ·Blood ·Brett Collinge, Lauren C. Chong, Susana Ben‐Neriah, Graham W. Slack, Daisuke Ennishi, Anja Mottok, Pedro Farinha, Merrill Boyle, Barbara Meissner, Alina S. Gerrie, Diego Villa, Kerry J. Savage, Laurie H. Sehn, Ryan D. Morin, Andrew J. Mungall, Randy D. Gascoyne, Marco A. Marra, Joseph M. Connors, Christian Steidl, David W. Scott	1
18	Association between insulin‐like growth factor‐1 polymorphisms and stomach cancer risk in a Japanese population 2011 ·Cancer Science ·Daisuke Ennishi, Kohei Shitara, Hidemi Ito, Satoyo Hosono, Miki Watanabe, Seiji Ito, Akira Sawaki, Yasushi Yatabe, Kenji Yamao, Kazuo Tajima, Mitsune Tanimoto, Hideo Tanaka, Nobuyuki Hamajima, Keitaro Matsuo	19
19	Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan. 2010 ·PubMed ·Hisakazu Nishimori, Shunji Takahashi, Katsuyuki Kiura, Daisuke Ennishi, Takayuki Kobayashi, Koji Sano, Eiji Shinozaki, Masahiro Yokoyama, Yuko Mishima, Yasuhito Terui, Keisho Chìn, Nobuyuki Mizunuma, Yoshinori Ito, Seiichiro Nishimura, Kengo Takeuchi, Yuichi Ishikawa, Masahiko Oguchi, Mitsune Tanimoto, Kiyohiko Hatake	5
20	An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy 2009 ·Clinical Cancer Research ·Yuji Mishima, Natsuhiko Sugimura, (unknown), Yasuhito Terui, Kengo Takeuchi, (unknown), Daisuke Ennishi, Hiroaki Asai, Masahiro Yokoyama, Kiyotsugu Kojima, Kiyohiko Hatake	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact